Myrexis Board of Directors Appoints Robert Lollini CEO
08 sept. 2011 16h01 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 8, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc., (Nasdaq:MYRX) today announced that its Board of Directors has appointed current interim President and Chief Executive Officer (CEO) and...
Myrexis to Hold Conference Call to Discuss Fiscal Year 2011 Results and Program Updates
02 sept. 2011 16h01 HE
|
Myrexis, Inc.
SALT LAKE CITY, Sept. 2, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on the development of small molecule compounds with novel chemical structures and...
Myrexis Announces Executive Management Changes
22 juil. 2011 08h30 HE
|
Myrexis, Inc.
SALT LAKE CITY, July 22, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that...
Myrexis to Participate in Stifel Nicolaus 2011 Orphan Drug One-on-One Conference
30 juin 2011 16h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, June 30, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that...
Myrexis Reports Azixa(R) Phase 2 Study Results at 2011 American Society of Clinical Oncology (ASCO) Annual Meeting
06 juin 2011 08h00 HE
|
Myrexis, Inc.
Azixa is Active and Well Tolerated in Patients Who Failed First-Line Therapy
Multi-Dose Efficacy Presented From Cancer Metabolism Inhibitor Program
SALT LAKE CITY, June 6, 2011 (GLOBE NEWSWIRE)...
Myrexis Presents Oral Anti-Interferon Preclinical Data at EULAR Annual European Congress of Rheumatology
26 mai 2011 16h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 26, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today presented encouraging...
Myrexis to Present at Jefferies 2011 Global Healthcare Conference
25 mai 2011 16h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 25, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced that Adrian...
Myrexis to Report Azixa(R) Phase 2 Study Results at 2011 American Society of Clinical Oncology (ASCO) Annual Meeting
18 mai 2011 18h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 18, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced it will...
Myrexis Reports Third Quarter Fiscal 2011 Results
10 mai 2011 16h15 HE
|
Myrexis, Inc.
Upcoming Events
Report Azixa® Phase 2a monotherapy results in recurrent glioblastoma multiforme (GBM) patients naive to treatment with Avastin® (bevacizumab) at American Society for...
Myrexis to Present Oral Anti-Interferon Program at EULAR Annual European Congress of Rheumatology
05 mai 2011 16h00 HE
|
Myrexis, Inc.
SALT LAKE CITY, May 5, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on developing and commercializing novel treatments for cancer, today announced it will...